Take Homes in Prostate Cancer

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discussed two studies that highlight positive results from darolutamide for prostate cancer.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses the Phase 3 VISION trial.

In this video, Eugene Shenderov, MD, PhD, discusses the STAMPEDE and PEACE-1 studies, which evaluated the addition of abiraterone acetate plus prednisolone to standard therapy for patients with prostate cancer.

In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

In this video, Alicia Morgans, MD, discusses the PEACE-1 phase 3 trial that found adding abiraterone to androgen deprivation therapy plus docetaxel improves radiographic PFS and OS in men with metastatic castration-sensitive prostate cancer.

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses a phase I/II multicenter first-in-human trial of DS-7300, an anti-B7-H3, which was studied in patients with advanced solid tumors.

In this video, Alicia K. Morgans, MD, discusses a study on the clinical and cost impact of cabazitaxel vs. a second androgen receptor targeted agent for patients with metastatic castration-resistant prostate cancer.